JERUSALEM, Nov. 4 (Xinhua) -- Israeli immunotherapy company Enlivex Therapeutics announced on Monday a success in trials of a drug for the treatment of severe sepsis.
Sepsis is a life-threatening medical condition caused by a body's immune response to a severe infection injures its own tissues and organs.
According to the World Health Organization, sepsis is estimated to affect more than 30 million people worldwide each year.
Enlivex developed the drug Allocetra, which rebalances a life-threatening unbalanced immune system, using the immune system's own natural regulation mechanisms.
The drug analysis included 43 patients with severe sepsis, all hospitalized at Hadassah Medical Center in Jerusalem.
Six of the 43 patients were treated with Allocetra, while the other 37 patients matched controls received standard of care treatment.
As the primary safety parameter was 28 days mortality, none of the six Allocetra-treated patients died during this period, compared with 11 of 37 (29 percent) in the matched control group who died during this period.
The company also reported that Allocetra treatment resulted in improved efficacy in all analyzed parameters, such as the sequential organ failure assessment (SOFA), score of the clinical condition of various organs, recovery and duration of intensive care hospitalization.
Enlivex was founded in 2012 and is based in the city of Ness Ziona in central Israel. It is traded at Nasdaq and the Tel Aviv Stock Exchange.
